PCP Addiction: Effects, Signs, Symptoms & Treatment

PCP is addictive: phencyclidine produces psychological dependence, craving, and compulsive use, and the DSM-5-TR diagnoses this pattern as phencyclidine use disorder, classified within the Hallucinogen-Related Disorders and assessed on 11 diagnostic criteria. Meeting 2 to 3 criteria indicates a mild disorder, 4 to 5 a moderate disorder, and 6 or more a severe disorder. Tolerance develops with repeated use, pushing people toward higher doses and more frequent binges.

One clinical distinction separates phencyclidine from alcohol, opioids, and benzodiazepines: the DSM-5-TR includes no phencyclidine withdrawal diagnosis, because a consistent physical withdrawal syndrome has not been established in humans. Dependence on PCP is driven by craving, tolerance, and loss of control rather than by a physical withdrawal syndrome. Phencyclidine use disorder also co-occurs at high rates with psychotic disorders, depression, and other substance use disorders, which is why dual diagnosis treatment that addresses the addiction and the psychiatric condition together is the standard of care. Recognizing the disorder starts with knowing the signs and symptoms of PCP use.

The signs of PCP use combine behavioral agitation, distinctive physical findings, and psychotic symptoms, and clinicians recognize the pattern by pairing bizarre or combative behavior with nystagmus — involuntary eye movements that can be vertical, horizontal, or rotary. Nystagmus in all three planes distinguishes phencyclidine intoxication from stimulant and alcohol intoxication on examination.

Behavioral signs include agitation, aggression and combativeness, disorientation, and bizarre or grandiose behavior such as undressing in public or claiming superhuman strength. Physical signs include nystagmus, numbness and analgesia in the extremities, ataxia (loss of coordination), muscle rigidity, elevated blood pressure, and elevated body temperature. Psychological signs include hallucinations, paranoia, delusions, dissociation from the body, and catatonia — rigid, unresponsive posturing. PCP-induced psychosis mirrors schizophrenia so closely that it underpins the NMDA-receptor hypofunction model of schizophrenia used in psychiatric research, and the same receptor mechanism drives ketamine addiction, phencyclidine's sibling dissociative. These signs escalate sharply with dose, which is why the effects and acute overdose risks of PCP demand their own examination.

PCP produces short-term dissociation, analgesia, and agitation, and high doses cause hyperthermia, rhabdomyolysis, seizures, hypertensive crisis, coma, and respiratory depression — a toxidrome that makes every high-dose PCP exposure a medical emergency. Low doses (1 to 5 mg) cause numbness, detachment, and slurred speech; higher doses produce psychosis, catatonia, and unconsciousness.

The most dangerous combination is profound analgesia paired with violent agitation. A person on PCP feels no pain, so they can break bones, lacerate skin, or fight through injuries that would stop anyone else — severe self-injury and accidental death are documented outcomes of phencyclidine intoxication. Acute overdose risks include hyperthermia, rhabdomyolysis — muscle breakdown that releases myoglobin and causes acute kidney failure — grand mal seizures, hypertensive crisis, coma, and respiratory depression at high doses. Any suspected drug overdose involving PCP is a 911 emergency. Long-term effects of repeated use include persistent memory and cognitive impairment, speech difficulty, depression, prolonged psychosis, and flashbacks that recur months after last use. After the acute effects fade, families often ask what PCP withdrawal or the comedown looks like.

PCP produces no established physical withdrawal syndrome in humans — the DSM-5-TR contains no phencyclidine withdrawal diagnosis — so discontinuation looks like a psychological comedown rather than the seizure-risk withdrawal seen with alcohol or benzodiazepines. The comedown after a PCP binge brings fatigue, depression, anxiety, intense craving, disturbed sleep, and cognitive fog that lasts days.

The dominant clinical risk after stopping PCP is psychiatric, not physical. PCP-induced psychosis can persist or recur for days to weeks after the drug clears, producing paranoia, hallucinations, and disorganized thinking that mimic a primary psychotic disorder and require psychiatric stabilization. Supervised medical monitoring remains warranted during the comedown period to manage agitation, dehydration, mood crashes, and safety risks, even though no taper protocol or withdrawal medication is required. Once the person is stable, the focus shifts to how PCP addiction is treated over the long term.

PCP and ketamine act on the same NMDA receptor but differ sharply in duration and safety profile: PCP intoxication lasts 4 to 6 hours or longer with a higher risk of violent agitation and prolonged psychosis, while ketamine’s effects resolve within 1 to 2 hours with a comparatively lower risk profile. Ketamine has a legitimate medical role — it is an FDA-approved surgical anesthetic, and its derivative esketamine (Spravato) is FDA-approved for treatment-resistant depression under medical supervision. PCP has no comparable medical pathway; it was withdrawn from clinical use in 1965 after patients experienced severe emergence delirium, and it remains a Schedule II drug with no approved therapeutic use today. Despite these differences, both drugs are treated with the same evidence-based approach: behavioral therapy addressing the psychological pattern of use, since neither has an FDA-approved medication for the substance use disorder itself.

PCP addiction is treated with supportive medical stabilization, integrated psychiatric care, and behavioral therapy, because no FDA-approved medication exists for phencyclidine use disorder. Treatment addresses the acute intoxication first, then the compulsive use pattern and any co-occurring psychiatric illness.

Acute management places the person in a low-stimulation environment with minimal noise and light, uses benzodiazepines to control agitation, and monitors for hyperthermia and rhabdomyolysis. Emergency clinicians avoid physical restraint whenever possible, because sustained struggling against restraints accelerates muscle breakdown and raises the risk of rhabdomyolysis and acute kidney failure. Ongoing care combines cognitive behavioral therapy (CBT), contingency management — a rewards-based protocol with strong evidence for stimulant and dissociative use disorders — and psychiatric treatment for persistent psychosis or depression. Ascend Recovery Center delivers this care across a partial hospitalization program (PHP) for clients who need full-day clinical structure and an intensive outpatient program (IOP) for clients balancing treatment with work or school. The final step is knowing how to get help for PCP addiction in Palm Beach Gardens.

Getting help for PCP addiction starts with a confidential clinical assessment and a free insurance verification, which determine the level of care matched to the severity of the phencyclidine use disorder and any co-occurring psychiatric condition. Because PCP use so often travels with psychosis, depression, or other substance use, the assessment evaluates the whole clinical picture — not the drug alone.

Ascend Recovery Center is a Joint Commission-accredited, Florida DCF-licensed outpatient treatment provider in Palm Beach Gardens serving clients across South Florida. An ASAM Criteria evaluation determines whether PHP, IOP, or outpatient care fits, and one integrated team treats the addiction and the co-occurring psychiatric condition together in a single coordinated plan. When acute psychiatric stabilization or medical detox is needed first, Ascend coordinates that placement and receives the client for step-down care. The admissions team verifies insurance benefits at no cost and answers questions the same day — call (561) 956-1082 to speak confidentially with an admissions specialist at Ascend Recovery Center.